Artrya utilizes AI-driven analysis of coronary computed tomography angiography (CCTA) to rapidly assess chest pain patients, enabling precise identification of arterial plaque and risk stratification within minutes. This technology addresses the high rates of undiagnosed coronary artery disease and unnecessary emergency department admissions, ultimately reducing healthcare costs and improving patient outcomes.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Coronary artery disease often goes undiagnosed, leading to high mortality rates and unnecessary emergency department admissions for chest pain patients. Traditional diagnostic approaches can be slow and may not provide a comprehensive assessment of arterial plaque characteristics. This can result in delayed treatment and increased healthcare costs.
Solution
Artrya offers an AI-powered analysis of coronary computed tomography angiography (CCTA) images to rapidly and precisely assess chest pain patients. The technology identifies and characterizes arterial plaque, providing clinicians with insights to stratify risk and guide treatment decisions within minutes. By integrating plaque features of high prognostic value, Artrya enables evidence-based decisions, potentially reducing unnecessary testing and moving patients to appropriate care settings. This approach aims to improve patient outcomes and reduce the economic burden associated with undiagnosed coronary artery disease.
Target Audience
Artrya's primary customers are physicians, hospitals, and healthcare systems that treat chest pain patients in emergency and primary care settings.
Features
- AI-driven analysis of CCTA images for rapid plaque assessment
- Identification and characterization of arterial plaque features
- Risk stratification of chest pain patients based on AI analysis
- Integration with existing clinical workflows
- Generation of evidence-based insights for informed decision-making